Jan Dalvise

About Jan Dalvise

Highly respected CEO and Board Director with 25+ years of experience in life sciences industry, including pharmaceuticals, medical devices, diagnostics, and discovery and translational research. Skilled in corporate strategic planning and operational execution, product/program development, and commercialization. Expertly translates market/medical needs into technical product specifications. Disciplined financial steward with proven track record in large and small organizations. Accomplished at building, managing, and funding start-ups and turning around struggling companies. Background in financial planning and corporate and business development. Proven fundraising track record, securing over $550M in combined equity, debt, and strategic capital to drive enterprise growth and development. Visionary and strategic thinker with a talent for identifying emerging market opportunities and implementing creative business and technology strategies to maximize commercial potential. Deep understanding of market dynamics, product marketing, sales, and pricing/reimbursement strategies. Resilient and versatile entrepreneur adept at navigating high-risk/high-reward environments, driving company toward success. HIGHLIGHTS: Extensive Finance and Audit, Strategy, Governance, and Compensation committee experience for public and private company boards, ensuring effective oversight and driving impactful decision-making. Raised >$150M in public markets and led Acasti\'s turnaround after a Phase 3 program failure. Completed an $80M strategic acquisition of Grace Therapeutics, advancing 2 rare and orphan drug programs from IND to Phase 3 in just 18 months. Co-founded, led and raised over $80M for 2 start-up companies (NuGEN and METRIKA) from concept to successful commercialization and eventual acquisition by major multinational companies. Turned around a struggling medical device company, Gish Biomedical. Achieved break-even within 6 months and orchestrated the profitable sale of the company to the Sorin Group, a global leader in Cardiopulmonary medical devices. Led strategic planning and sale of the struggling non-profit cancer institute (SKCC) to the Sanford Burnham Prebys Institute, preserving its scientific personnel and grant programs through a successful M&A transaction valued at more than $40M. Achieved combined upfronts of $250M+ through the execution of numerous out-licensing, co-development, and commercialization transactions, primarily in the clinical diagnostic sector.

Experience

1. Acting Chief Executive Officer

   Radioeye

   Jul 2023 — Present · San Diego, DE

   Leading founding team to complete product development of the RadioEye AI decision support software tool designed to improve efficiency and diagnostic accuracy for Radiologists. Developing and implementing a US/global business and commercialization strategy and plan, and finalizing regulatory pathway and strategy with goal to receive FDA approval and commercial launch in 2024.

Education

• Michigan Technological University

  BS

• University of Michigan

  MBA Coursework